 Uwe Christians
Concepts (1145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunosuppressive Agents | 133 | 2024 | 838 | 11.480 |
Why?
| | Sirolimus | 60 | 2025 | 282 | 6.580 |
Why?
| | Cyclosporine | 74 | 2019 | 256 | 6.150 |
Why?
| | Tandem Mass Spectrometry | 41 | 2026 | 572 | 5.460 |
Why?
| | Tacrolimus | 47 | 2025 | 196 | 4.350 |
Why?
| | Chromatography, High Pressure Liquid | 69 | 2026 | 592 | 4.310 |
Why?
| | Kidney Transplantation | 47 | 2025 | 712 | 3.520 |
Why?
| | Drug Monitoring | 23 | 2020 | 401 | 3.000 |
Why?
| | Metabolomics | 19 | 2025 | 733 | 2.720 |
Why?
| | Chromatography, Liquid | 27 | 2026 | 450 | 2.480 |
Why?
| | Mycophenolic Acid | 15 | 2017 | 119 | 2.250 |
Why?
| | Kidney | 25 | 2022 | 1497 | 2.100 |
Why?
| | Microsomes, Liver | 19 | 2019 | 85 | 1.980 |
Why?
| | Everolimus | 25 | 2020 | 112 | 1.900 |
Why?
| | Mass Spectrometry | 34 | 2021 | 732 | 1.750 |
Why?
| | Cannabinoids | 12 | 2026 | 184 | 1.740 |
Why?
| | Dronabinol | 17 | 2026 | 249 | 1.700 |
Why?
| | Biomarkers | 29 | 2025 | 4302 | 1.690 |
Why?
| | Graft Rejection | 26 | 2019 | 521 | 1.350 |
Why?
| | Liver Transplantation | 28 | 2018 | 827 | 1.290 |
Why?
| | Substance Abuse Detection | 5 | 2026 | 110 | 1.270 |
Why?
| | Proteomics | 18 | 2024 | 1188 | 1.200 |
Why?
| | Cannabidiol | 7 | 2025 | 142 | 1.110 |
Why?
| | Plant Extracts | 6 | 2024 | 188 | 1.080 |
Why?
| | Cannabis | 12 | 2024 | 510 | 1.050 |
Why?
| | Cyclophilins | 2 | 2017 | 40 | 1.010 |
Why?
| | Humans | 247 | 2026 | 145783 | 1.010 |
Why?
| | Rats | 63 | 2026 | 5585 | 1.010 |
Why?
| | Oxidative Stress | 17 | 2019 | 1360 | 0.990 |
Why?
| | Metabolome | 6 | 2025 | 391 | 0.990 |
Why?
| | Cytochrome P-450 CYP3A | 20 | 2021 | 93 | 0.990 |
Why?
| | Proto-Oncogene Proteins c-akt | 4 | 2017 | 440 | 0.960 |
Why?
| | Organ Transplantation | 10 | 2019 | 253 | 0.960 |
Why?
| | Hallucinogens | 6 | 2024 | 111 | 0.950 |
Why?
| | Xylazine | 1 | 2026 | 16 | 0.930 |
Why?
| | Pravastatin | 9 | 2021 | 45 | 0.920 |
Why?
| | Dried Blood Spot Testing | 3 | 2020 | 126 | 0.920 |
Why?
| | Hydrocortisone | 3 | 2025 | 298 | 0.900 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 8 | 2019 | 174 | 0.890 |
Why?
| | Drug Interactions | 27 | 2025 | 405 | 0.890 |
Why?
| | Reproducibility of Results | 27 | 2025 | 3418 | 0.870 |
Why?
| | Immunoassay | 3 | 2020 | 109 | 0.860 |
Why?
| | Allografts | 1 | 2025 | 152 | 0.850 |
Why?
| | Cytochrome P-450 Enzyme System | 17 | 2019 | 162 | 0.850 |
Why?
| | Animals | 123 | 2026 | 38102 | 0.820 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 7 | 2022 | 235 | 0.800 |
Why?
| | Male | 147 | 2026 | 73011 | 0.780 |
Why?
| | Proteome | 5 | 2017 | 513 | 0.770 |
Why?
| | Kidney Failure, Chronic | 5 | 2025 | 599 | 0.760 |
Why?
| | Mitochondria | 6 | 2017 | 993 | 0.760 |
Why?
| | Lovastatin | 7 | 2013 | 37 | 0.750 |
Why?
| | Drugs, Generic | 4 | 2019 | 28 | 0.750 |
Why?
| | Female | 123 | 2026 | 79045 | 0.750 |
Why?
| | Factor Xa Inhibitors | 2 | 2025 | 194 | 0.740 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 9 | 2015 | 444 | 0.730 |
Why?
| | Nucleotides | 2 | 2017 | 129 | 0.720 |
Why?
| | Pharmaceutical Preparations | 3 | 2017 | 171 | 0.700 |
Why?
| | Isoprostanes | 4 | 2012 | 15 | 0.700 |
Why?
| | Intestinal Mucosa | 7 | 2017 | 675 | 0.700 |
Why?
| | Magnetic Resonance Spectroscopy | 18 | 2017 | 627 | 0.690 |
Why?
| | United States Food and Drug Administration | 3 | 2020 | 208 | 0.690 |
Why?
| | Biological Availability | 12 | 2019 | 145 | 0.690 |
Why?
| | Cortisone | 1 | 2021 | 16 | 0.690 |
Why?
| | Adaptation, Physiological | 2 | 2025 | 560 | 0.690 |
Why?
| | Dose-Response Relationship, Drug | 27 | 2026 | 2028 | 0.690 |
Why?
| | Pregnanolone | 1 | 2021 | 34 | 0.660 |
Why?
| | Cyclosporins | 18 | 2001 | 71 | 0.650 |
Why?
| | Endocannabinoids | 5 | 2025 | 56 | 0.650 |
Why?
| | TOR Serine-Threonine Kinases | 7 | 2016 | 456 | 0.650 |
Why?
| | Urine | 2 | 2017 | 64 | 0.640 |
Why?
| | Transplant Recipients | 4 | 2019 | 182 | 0.640 |
Why?
| | Estrogen Receptor beta | 2 | 2012 | 40 | 0.630 |
Why?
| | Drug-Eluting Stents | 7 | 2025 | 88 | 0.630 |
Why?
| | Energy Metabolism | 17 | 2022 | 935 | 0.620 |
Why?
| | Dinoprost | 6 | 2019 | 51 | 0.620 |
Why?
| | Progesterone | 1 | 2021 | 215 | 0.610 |
Why?
| | Therapeutic Equivalency | 6 | 2019 | 31 | 0.600 |
Why?
| | Limit of Detection | 11 | 2024 | 92 | 0.590 |
Why?
| | Pharmacology | 1 | 2019 | 10 | 0.590 |
Why?
| | Substance-Related Disorders | 2 | 2026 | 1103 | 0.580 |
Why?
| | Hemorrhage | 2 | 2025 | 822 | 0.580 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 6 | 2004 | 45 | 0.580 |
Why?
| | Tissue Distribution | 12 | 2019 | 335 | 0.570 |
Why?
| | Brain | 14 | 2026 | 2969 | 0.560 |
Why?
| | Signal Transduction | 11 | 2017 | 5224 | 0.550 |
Why?
| | Models, Biological | 9 | 2021 | 1764 | 0.550 |
Why?
| | Analgesics, Opioid | 9 | 2025 | 1154 | 0.550 |
Why?
| | Therapies, Investigational | 1 | 2017 | 19 | 0.520 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 36 | 0.520 |
Why?
| | Intestine, Small | 5 | 2006 | 167 | 0.510 |
Why?
| | Rats, Wistar | 16 | 2024 | 450 | 0.510 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2017 | 32 | 0.510 |
Why?
| | Cardiovascular Agents | 5 | 2025 | 166 | 0.500 |
Why?
| | Toxicity Tests | 1 | 2017 | 53 | 0.500 |
Why?
| | Menopause | 3 | 2019 | 326 | 0.500 |
Why?
| | Prenatal Exposure Delayed Effects | 6 | 2024 | 655 | 0.500 |
Why?
| | Administration, Oral | 15 | 2026 | 867 | 0.500 |
Why?
| | Myocardium | 4 | 2017 | 935 | 0.480 |
Why?
| | Anisakis | 1 | 2016 | 2 | 0.470 |
Why?
| | Helminth Proteins | 1 | 2016 | 24 | 0.470 |
Why?
| | Anticoagulants | 2 | 2020 | 748 | 0.460 |
Why?
| | Choline | 3 | 2022 | 138 | 0.460 |
Why?
| | Marijuana Smoking | 4 | 2025 | 249 | 0.460 |
Why?
| | Lipid Metabolism | 2 | 2017 | 529 | 0.450 |
Why?
| | Kidney Diseases | 3 | 2018 | 426 | 0.450 |
Why?
| | Fishes | 1 | 2016 | 110 | 0.450 |
Why?
| | MAP Kinase Signaling System | 1 | 2017 | 308 | 0.440 |
Why?
| | Clinical Laboratory Techniques | 1 | 2015 | 96 | 0.440 |
Why?
| | Oxidoreductases, N-Demethylating | 6 | 2004 | 17 | 0.430 |
Why?
| | Adult | 65 | 2026 | 40881 | 0.430 |
Why?
| | Gastrointestinal Tract | 1 | 2017 | 204 | 0.420 |
Why?
| | Sensitivity and Specificity | 12 | 2024 | 2000 | 0.420 |
Why?
| | Fingolimod Hydrochloride | 2 | 2024 | 40 | 0.410 |
Why?
| | Amino Acids | 3 | 2016 | 519 | 0.400 |
Why?
| | Multiprotein Complexes | 1 | 2015 | 172 | 0.400 |
Why?
| | Polyenes | 8 | 1998 | 17 | 0.400 |
Why?
| | Premature Birth | 3 | 2025 | 390 | 0.400 |
Why?
| | Hydroxyurea | 1 | 2013 | 34 | 0.390 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2013 | 34 | 0.390 |
Why?
| | Molecular Structure | 10 | 2014 | 487 | 0.390 |
Why?
| | Metabolic Clearance Rate | 9 | 2019 | 115 | 0.390 |
Why?
| | Protein Kinases | 4 | 2017 | 312 | 0.390 |
Why?
| | Anticholesteremic Agents | 4 | 2007 | 155 | 0.390 |
Why?
| | Liver | 15 | 2026 | 1899 | 0.390 |
Why?
| | Piperazines | 4 | 2009 | 375 | 0.380 |
Why?
| | Coated Materials, Biocompatible | 3 | 2020 | 65 | 0.370 |
Why?
| | Cerebrospinal Fluid | 1 | 2013 | 88 | 0.370 |
Why?
| | Transplantation, Homologous | 9 | 2025 | 419 | 0.370 |
Why?
| | Sodium Chloride, Dietary | 1 | 2012 | 31 | 0.370 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2021 | 849 | 0.360 |
Why?
| | Drug Therapy, Combination | 18 | 2025 | 1043 | 0.360 |
Why?
| | Pyrimidines | 4 | 2014 | 530 | 0.360 |
Why?
| | In Vitro Techniques | 18 | 2017 | 1049 | 0.360 |
Why?
| | Middle Aged | 50 | 2025 | 36309 | 0.360 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2012 | 34 | 0.360 |
Why?
| | Heart Transplantation | 8 | 2017 | 680 | 0.360 |
Why?
| | Vasomotor System | 1 | 2012 | 47 | 0.360 |
Why?
| | Macrophages, Alveolar | 4 | 2016 | 373 | 0.340 |
Why?
| | Antineoplastic Agents | 7 | 2020 | 2219 | 0.340 |
Why?
| | Double-Blind Method | 12 | 2026 | 2064 | 0.340 |
Why?
| | Rats, Sprague-Dawley | 19 | 2026 | 2525 | 0.340 |
Why?
| | Hypoxia | 6 | 2024 | 1199 | 0.340 |
Why?
| | Young Adult | 26 | 2026 | 14254 | 0.330 |
Why?
| | Prospective Studies | 19 | 2025 | 8078 | 0.330 |
Why?
| | Adolescent | 31 | 2025 | 22577 | 0.330 |
Why?
| | Area Under Curve | 9 | 2021 | 332 | 0.330 |
Why?
| | Lung Transplantation | 8 | 2000 | 332 | 0.330 |
Why?
| | Neonatal Abstinence Syndrome | 2 | 2021 | 27 | 0.330 |
Why?
| | Microsomes | 5 | 1998 | 33 | 0.320 |
Why?
| | Swine | 15 | 2017 | 826 | 0.320 |
Why?
| | Child | 26 | 2025 | 22740 | 0.320 |
Why?
| | Artifacts | 1 | 2011 | 143 | 0.320 |
Why?
| | Disease Models, Animal | 13 | 2026 | 4568 | 0.310 |
Why?
| | Acetaminophen | 1 | 2013 | 267 | 0.310 |
Why?
| | Hydroxylation | 5 | 2019 | 47 | 0.310 |
Why?
| | Graft Survival | 6 | 2018 | 519 | 0.300 |
Why?
| | Calcineurin Inhibitors | 6 | 2014 | 69 | 0.300 |
Why?
| | Phosphates | 5 | 2012 | 177 | 0.300 |
Why?
| | Drug Approval | 1 | 2010 | 93 | 0.300 |
Why?
| | Cell Proliferation | 10 | 2020 | 2514 | 0.290 |
Why?
| | Bile | 7 | 1992 | 26 | 0.290 |
Why?
| | Isoniazid | 2 | 2006 | 70 | 0.290 |
Why?
| | Lidocaine | 2 | 2023 | 55 | 0.290 |
Why?
| | Theophylline | 2 | 2020 | 41 | 0.290 |
Why?
| | Endothelium, Vascular | 4 | 2019 | 956 | 0.290 |
Why?
| | Diltiazem | 3 | 1997 | 17 | 0.280 |
Why?
| | Glucose | 7 | 2017 | 1049 | 0.280 |
Why?
| | Time Factors | 19 | 2025 | 7134 | 0.280 |
Why?
| | Flavanones | 1 | 2008 | 6 | 0.280 |
Why?
| | Medical Marijuana | 2 | 2021 | 122 | 0.280 |
Why?
| | Drugs, Chinese Herbal | 1 | 2008 | 24 | 0.280 |
Why?
| | Paclitaxel | 3 | 2020 | 259 | 0.280 |
Why?
| | Cross-Over Studies | 6 | 2025 | 610 | 0.270 |
Why?
| | HIV Protease Inhibitors | 3 | 2019 | 69 | 0.270 |
Why?
| | Pregnancy | 13 | 2025 | 7216 | 0.270 |
Why?
| | Child, Preschool | 13 | 2025 | 11868 | 0.270 |
Why?
| | Neurons | 3 | 2019 | 1652 | 0.270 |
Why?
| | Liver Function Tests | 5 | 2025 | 105 | 0.270 |
Why?
| | Biotransformation | 18 | 2021 | 62 | 0.260 |
Why?
| | Calcium Channel Blockers | 3 | 1997 | 166 | 0.260 |
Why?
| | Mice | 21 | 2026 | 18356 | 0.260 |
Why?
| | Mice, Knockout | 7 | 2026 | 3130 | 0.260 |
Why?
| | Buprenorphine | 2 | 2021 | 192 | 0.260 |
Why?
| | Angioplasty, Balloon | 3 | 2020 | 94 | 0.250 |
Why?
| | Naltrexone | 1 | 2008 | 115 | 0.250 |
Why?
| | Drug Stability | 4 | 2013 | 169 | 0.250 |
Why?
| | Pyridostigmine Bromide | 1 | 2006 | 5 | 0.250 |
Why?
| | Lipase | 2 | 2020 | 75 | 0.250 |
Why?
| | Half-Life | 8 | 2019 | 155 | 0.240 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2006 | 41 | 0.240 |
Why?
| | Tachycardia | 1 | 2006 | 58 | 0.240 |
Why?
| | Cholinesterase Inhibitors | 1 | 2006 | 47 | 0.240 |
Why?
| | Coronary Artery Disease | 3 | 2025 | 750 | 0.240 |
Why?
| | Glomerular Filtration Rate | 8 | 2022 | 765 | 0.240 |
Why?
| | Reactive Oxygen Species | 4 | 2010 | 611 | 0.240 |
Why?
| | Macaca fascicularis | 13 | 2008 | 70 | 0.230 |
Why?
| | Regression Analysis | 5 | 2020 | 1001 | 0.230 |
Why?
| | Cannabinoid Receptor Agonists | 5 | 2024 | 44 | 0.230 |
Why?
| | Drug Carriers | 2 | 2020 | 136 | 0.230 |
Why?
| | Postoperative Complications | 6 | 2025 | 2977 | 0.230 |
Why?
| | Iodide Peroxidase | 1 | 2026 | 35 | 0.230 |
Why?
| | Fibrinolytic Agents | 2 | 2025 | 297 | 0.230 |
Why?
| | Anti-Bacterial Agents | 6 | 2025 | 1925 | 0.230 |
Why?
| | Dogs | 6 | 2025 | 478 | 0.230 |
Why?
| | Pipecolic Acids | 1 | 2025 | 26 | 0.230 |
Why?
| | Coronary Thrombosis | 1 | 2025 | 25 | 0.230 |
Why?
| | Mice, Inbred C57BL | 11 | 2026 | 5993 | 0.230 |
Why?
| | Abdominal Neoplasms | 1 | 2025 | 47 | 0.230 |
Why?
| | Drug Delivery Systems | 4 | 2020 | 381 | 0.220 |
Why?
| | Isomerism | 2 | 2024 | 56 | 0.220 |
Why?
| | Corticosterone | 2 | 2024 | 241 | 0.220 |
Why?
| | Heptanoic Acids | 2 | 2007 | 67 | 0.220 |
Why?
| | Cell Line, Tumor | 8 | 2017 | 3551 | 0.220 |
Why?
| | Hyperglycinemia, Nonketotic | 1 | 2026 | 56 | 0.220 |
Why?
| | Depression | 3 | 2025 | 1559 | 0.220 |
Why?
| | Catheters | 2 | 2017 | 74 | 0.220 |
Why?
| | Drug Synergism | 7 | 2014 | 354 | 0.220 |
Why?
| | Caffeine | 1 | 2025 | 74 | 0.220 |
Why?
| | Cell-Derived Microparticles | 2 | 2018 | 73 | 0.220 |
Why?
| | Serine | 1 | 2026 | 143 | 0.220 |
Why?
| | Secologanin Tryptamine Alkaloids | 1 | 2024 | 4 | 0.220 |
Why?
| | Cholic Acid | 1 | 2024 | 4 | 0.220 |
Why?
| | Epilepsy | 2 | 2020 | 390 | 0.220 |
Why?
| | Alkaloids | 1 | 2024 | 28 | 0.220 |
Why?
| | Oxylipins | 1 | 2025 | 47 | 0.220 |
Why?
| | Mitragyna | 1 | 2024 | 8 | 0.210 |
Why?
| | Attention | 2 | 2026 | 463 | 0.210 |
Why?
| | Clemastine | 1 | 2024 | 1 | 0.210 |
Why?
| | Glycine | 1 | 2026 | 186 | 0.210 |
Why?
| | Wound Infection | 1 | 2025 | 60 | 0.210 |
Why?
| | Enzyme Inhibitors | 4 | 2012 | 821 | 0.210 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2019 | 440 | 0.210 |
Why?
| | Inflammation | 9 | 2025 | 2884 | 0.210 |
Why?
| | Infant, Newborn | 12 | 2024 | 6465 | 0.210 |
Why?
| | Ketorolac | 2 | 2017 | 33 | 0.210 |
Why?
| | Benzylidene Compounds | 2 | 2017 | 20 | 0.210 |
Why?
| | Diphosphonates | 1 | 2025 | 68 | 0.210 |
Why?
| | Bezafibrate | 1 | 2024 | 10 | 0.210 |
Why?
| | Acyl-CoA Dehydrogenases | 1 | 2024 | 12 | 0.210 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2004 | 87 | 0.210 |
Why?
| | Folic Acid | 1 | 2026 | 198 | 0.210 |
Why?
| | Cholesterol | 5 | 2013 | 408 | 0.210 |
Why?
| | Pyridinium Compounds | 1 | 2024 | 31 | 0.210 |
Why?
| | Kinetics | 8 | 2013 | 1568 | 0.210 |
Why?
| | Gene Expression Profiling | 1 | 2011 | 1777 | 0.210 |
Why?
| | Antibiotic Prophylaxis | 1 | 2025 | 134 | 0.210 |
Why?
| | Pyrroles | 2 | 2007 | 220 | 0.210 |
Why?
| | Animals, Newborn | 3 | 2024 | 896 | 0.200 |
Why?
| | Protease Inhibitors | 1 | 2004 | 102 | 0.200 |
Why?
| | Cell Line | 7 | 2017 | 2823 | 0.200 |
Why?
| | Birth Weight | 2 | 2024 | 517 | 0.200 |
Why?
| | Glycerides | 1 | 2024 | 16 | 0.200 |
Why?
| | Acidosis, Lactic | 1 | 2024 | 46 | 0.200 |
Why?
| | Morphine | 2 | 2018 | 169 | 0.200 |
Why?
| | Arachidonic Acids | 1 | 2024 | 42 | 0.200 |
Why?
| | Gestational Age | 3 | 2022 | 990 | 0.200 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2006 | 238 | 0.200 |
Why?
| | Central Nervous System Stimulants | 1 | 2025 | 185 | 0.200 |
Why?
| | Myocardial Infarction | 3 | 2026 | 1211 | 0.200 |
Why?
| | Deoxycytidine | 1 | 2025 | 220 | 0.200 |
Why?
| | Leukemia | 2 | 2020 | 246 | 0.200 |
Why?
| | Macrolides | 1 | 2003 | 67 | 0.190 |
Why?
| | Niacinamide | 1 | 2024 | 104 | 0.190 |
Why?
| | Mixed Function Oxygenases | 5 | 2001 | 43 | 0.190 |
Why?
| | Rivaroxaban | 1 | 2025 | 271 | 0.190 |
Why?
| | Adiponectin | 1 | 2025 | 242 | 0.190 |
Why?
| | Transplantation | 4 | 2016 | 33 | 0.190 |
Why?
| | Anti-HIV Agents | 3 | 2013 | 912 | 0.190 |
Why?
| | Analgesia | 1 | 2024 | 106 | 0.190 |
Why?
| | Neurofibromatosis 1 | 2 | 2015 | 57 | 0.190 |
Why?
| | Glycolysis | 4 | 2012 | 340 | 0.190 |
Why?
| | Psychomotor Performance | 1 | 2025 | 324 | 0.190 |
Why?
| | Blotting, Western | 8 | 2012 | 1184 | 0.180 |
Why?
| | Hepatitis C | 1 | 2005 | 256 | 0.180 |
Why?
| | Opioid-Related Disorders | 2 | 2021 | 605 | 0.180 |
Why?
| | Rats, Inbred Lew | 11 | 2012 | 105 | 0.180 |
Why?
| | White Matter | 1 | 2024 | 155 | 0.180 |
Why?
| | Glutamine | 3 | 2012 | 109 | 0.180 |
Why?
| | Pharmacogenetics | 3 | 2010 | 175 | 0.180 |
Why?
| | Blood Transfusion | 1 | 2025 | 409 | 0.180 |
Why?
| | Fetal Growth Retardation | 2 | 2018 | 593 | 0.180 |
Why?
| | Infant, Small for Gestational Age | 1 | 2022 | 118 | 0.180 |
Why?
| | Aminophylline | 2 | 2020 | 12 | 0.170 |
Why?
| | Homocysteine | 2 | 2019 | 152 | 0.170 |
Why?
| | Adrenal Cortex Hormones | 2 | 2021 | 484 | 0.170 |
Why?
| | Heart Rate, Fetal | 1 | 2021 | 31 | 0.170 |
Why?
| | TRPP Cation Channels | 1 | 2022 | 74 | 0.170 |
Why?
| | Kynurenine | 2 | 2022 | 114 | 0.170 |
Why?
| | Prostaglandins | 2 | 2019 | 94 | 0.170 |
Why?
| | Biological Transport, Active | 5 | 2006 | 69 | 0.170 |
Why?
| | Transplantation, Heterologous | 3 | 2006 | 170 | 0.170 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2023 | 185 | 0.170 |
Why?
| | Arginine | 2 | 2025 | 264 | 0.170 |
Why?
| | Fetal Development | 2 | 2021 | 298 | 0.170 |
Why?
| | Aged | 19 | 2025 | 26217 | 0.170 |
Why?
| | Myocytes, Cardiac | 1 | 2026 | 546 | 0.170 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2014 | 128 | 0.160 |
Why?
| | Hepatectomy | 2 | 2023 | 274 | 0.160 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 5 | 2012 | 110 | 0.160 |
Why?
| | Hypoxia-Ischemia, Brain | 2 | 2020 | 50 | 0.160 |
Why?
| | Pilot Projects | 8 | 2023 | 1898 | 0.160 |
Why?
| | Pain | 2 | 2025 | 791 | 0.160 |
Why?
| | gamma-Aminobutyric Acid | 2 | 2018 | 194 | 0.160 |
Why?
| | Marijuana Abuse | 1 | 2023 | 214 | 0.160 |
Why?
| | Anesthetics, Intravenous | 2 | 2016 | 69 | 0.160 |
Why?
| | Avoidance Learning | 2 | 2024 | 63 | 0.160 |
Why?
| | Hypothalamus | 2 | 2018 | 163 | 0.160 |
Why?
| | Organic Anion Transporters | 2 | 2011 | 13 | 0.160 |
Why?
| | Microspheres | 2 | 2020 | 142 | 0.160 |
Why?
| | Complement Pathway, Alternative | 2 | 2018 | 121 | 0.160 |
Why?
| | Coronary Restenosis | 2 | 2010 | 22 | 0.160 |
Why?
| | Cardiomyopathies | 1 | 2024 | 335 | 0.160 |
Why?
| | Keratosis | 1 | 2020 | 16 | 0.160 |
Why?
| | Glutamic Acid | 2 | 2018 | 255 | 0.160 |
Why?
| | Lactones | 1 | 2000 | 59 | 0.160 |
Why?
| | Heart Defects, Congenital | 2 | 2018 | 910 | 0.160 |
Why?
| | Infusions, Intravenous | 4 | 2018 | 428 | 0.160 |
Why?
| | Losartan | 1 | 2000 | 13 | 0.160 |
Why?
| | Infant | 11 | 2024 | 10091 | 0.150 |
Why?
| | Complement Activation | 3 | 2018 | 399 | 0.150 |
Why?
| | Cytochrome P-450 CYP2C8 | 1 | 2019 | 14 | 0.150 |
Why?
| | Treatment Outcome | 12 | 2025 | 11794 | 0.150 |
Why?
| | Volatilization | 1 | 2019 | 45 | 0.150 |
Why?
| | Pyridines | 2 | 2017 | 609 | 0.150 |
Why?
| | Tetrazoles | 1 | 2000 | 50 | 0.150 |
Why?
| | Amygdala | 3 | 2024 | 200 | 0.150 |
Why?
| | L-Lactate Dehydrogenase | 2 | 2017 | 112 | 0.150 |
Why?
| | Reference Standards | 5 | 2016 | 177 | 0.150 |
Why?
| | Carotid Arteries | 2 | 2018 | 208 | 0.150 |
Why?
| | Nebulizers and Vaporizers | 1 | 2019 | 62 | 0.150 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2025 | 549 | 0.150 |
Why?
| | Brain Chemistry | 1 | 2000 | 120 | 0.150 |
Why?
| | Adenosine | 4 | 2017 | 255 | 0.150 |
Why?
| | Retrospective Studies | 10 | 2026 | 17330 | 0.150 |
Why?
| | Angiotensin II | 1 | 2000 | 102 | 0.150 |
Why?
| | Age Factors | 7 | 2018 | 3346 | 0.150 |
Why?
| | Milk, Human | 1 | 2021 | 175 | 0.150 |
Why?
| | Case-Control Studies | 7 | 2025 | 3634 | 0.150 |
Why?
| | Astrocytes | 4 | 2011 | 228 | 0.150 |
Why?
| | Persian Gulf Syndrome | 1 | 2019 | 18 | 0.150 |
Why?
| | Hypothermia, Induced | 1 | 2020 | 96 | 0.150 |
Why?
| | Mice, 129 Strain | 1 | 2019 | 85 | 0.150 |
Why?
| | Leukotrienes | 1 | 2019 | 28 | 0.150 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 2 | 2017 | 94 | 0.150 |
Why?
| | Spine | 1 | 2021 | 182 | 0.140 |
Why?
| | Mental Disorders | 2 | 2021 | 1171 | 0.140 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2000 | 144 | 0.140 |
Why?
| | Opiate Substitution Treatment | 1 | 2021 | 189 | 0.140 |
Why?
| | Breast Neoplasms | 2 | 2011 | 2393 | 0.140 |
Why?
| | Perfusion | 6 | 2017 | 251 | 0.140 |
Why?
| | Vascular Diseases | 2 | 2019 | 252 | 0.140 |
Why?
| | Fentanyl | 2 | 2011 | 128 | 0.140 |
Why?
| | Taurine | 1 | 2019 | 41 | 0.140 |
Why?
| | Bilirubin | 3 | 1995 | 99 | 0.140 |
Why?
| | Cystathionine beta-Synthase | 1 | 2019 | 65 | 0.140 |
Why?
| | Coronary Care Units | 1 | 2018 | 27 | 0.140 |
Why?
| | Caspase 3 | 2 | 2017 | 242 | 0.140 |
Why?
| | Metabolic Networks and Pathways | 1 | 2019 | 175 | 0.140 |
Why?
| | Imidazoles | 1 | 2000 | 247 | 0.140 |
Why?
| | Legislation, Drug | 1 | 1999 | 73 | 0.140 |
Why?
| | Atmospheric Pressure | 3 | 2021 | 26 | 0.140 |
Why?
| | Homocystinuria | 1 | 2019 | 62 | 0.140 |
Why?
| | Systems Biology | 1 | 2019 | 68 | 0.140 |
Why?
| | Complement Factor D | 1 | 2018 | 28 | 0.140 |
Why?
| | Naphthalenes | 1 | 1998 | 54 | 0.140 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 334 | 0.140 |
Why?
| | Phosphocreatine | 3 | 2004 | 44 | 0.140 |
Why?
| | Creatinine | 5 | 2022 | 515 | 0.140 |
Why?
| | Iohexol | 1 | 2018 | 23 | 0.140 |
Why?
| | Methadone | 1 | 2020 | 123 | 0.140 |
Why?
| | Reference Values | 4 | 2013 | 798 | 0.130 |
Why?
| | Enzyme Activation | 2 | 2017 | 762 | 0.130 |
Why?
| | DNA Damage | 2 | 2019 | 437 | 0.130 |
Why?
| | Excipients | 1 | 2018 | 55 | 0.130 |
Why?
| | Phospholipids | 5 | 2013 | 214 | 0.130 |
Why?
| | Genotype | 5 | 2019 | 1857 | 0.130 |
Why?
| | Lysophosphatidylcholines | 1 | 2017 | 23 | 0.130 |
Why?
| | Anticonvulsants | 1 | 2020 | 246 | 0.130 |
Why?
| | Diet, Ketogenic | 1 | 2018 | 39 | 0.130 |
Why?
| | Vascular Access Devices | 1 | 2018 | 30 | 0.130 |
Why?
| | Glucuronides | 2 | 2022 | 18 | 0.130 |
Why?
| | Phenylpropionates | 1 | 2017 | 27 | 0.130 |
Why?
| | Cysteine | 1 | 2019 | 211 | 0.130 |
Why?
| | Complement Factor B | 1 | 2018 | 106 | 0.130 |
Why?
| | Cells, Cultured | 10 | 2017 | 4151 | 0.130 |
Why?
| | Prognosis | 5 | 2025 | 4330 | 0.130 |
Why?
| | Terbutaline | 1 | 2017 | 7 | 0.130 |
Why?
| | Endothelins | 1 | 2017 | 61 | 0.130 |
Why?
| | Sex Factors | 3 | 2019 | 2110 | 0.130 |
Why?
| | Pyridazines | 1 | 2017 | 57 | 0.130 |
Why?
| | Kidney Glomerulus | 1 | 2018 | 125 | 0.130 |
Why?
| | Enzyme Stability | 1 | 2017 | 73 | 0.130 |
Why?
| | Guanosine | 1 | 2017 | 40 | 0.130 |
Why?
| | Antineoplastic Agents, Phytogenic | 2 | 2017 | 178 | 0.130 |
Why?
| | Maternal Exposure | 1 | 2019 | 189 | 0.130 |
Why?
| | Acute Kidney Injury | 2 | 2018 | 874 | 0.130 |
Why?
| | Endothelium | 2 | 2014 | 119 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 136 | 0.130 |
Why?
| | Complement Factor H | 1 | 2018 | 79 | 0.130 |
Why?
| | Wounds and Injuries | 1 | 2025 | 962 | 0.120 |
Why?
| | Protein Kinase Inhibitors | 4 | 2014 | 981 | 0.120 |
Why?
| | Quality Control | 4 | 2021 | 161 | 0.120 |
Why?
| | Single-Blind Method | 1 | 2017 | 318 | 0.120 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 172 | 0.120 |
Why?
| | Glutathione | 4 | 2009 | 370 | 0.120 |
Why?
| | Immunoglobulin M | 1 | 2018 | 265 | 0.120 |
Why?
| | Cardiopulmonary Bypass | 1 | 2018 | 219 | 0.120 |
Why?
| | Plasma | 2 | 2017 | 223 | 0.120 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2014 | 68 | 0.120 |
Why?
| | Ischemia | 2 | 2012 | 422 | 0.120 |
Why?
| | Malathion | 1 | 2016 | 3 | 0.120 |
Why?
| | Necrosis | 1 | 2017 | 244 | 0.120 |
Why?
| | Arthritis, Rheumatoid | 1 | 2025 | 1180 | 0.120 |
Why?
| | Air Pollution | 1 | 2019 | 315 | 0.120 |
Why?
| | Bronchoalveolar Lavage Fluid | 3 | 2016 | 638 | 0.120 |
Why?
| | Vitamin D | 1 | 2019 | 404 | 0.120 |
Why?
| | Laboratory Proficiency Testing | 1 | 2015 | 9 | 0.120 |
Why?
| | Bone Marrow Transplantation | 2 | 1996 | 298 | 0.120 |
Why?
| | Myocardial Reperfusion Injury | 3 | 2007 | 139 | 0.120 |
Why?
| | Tunica Intima | 2 | 2010 | 78 | 0.110 |
Why?
| | Pregnancy Complications | 1 | 2021 | 603 | 0.110 |
Why?
| | Mutation | 2 | 2022 | 4090 | 0.110 |
Why?
| | Propofol | 1 | 2016 | 85 | 0.110 |
Why?
| | Imatinib Mesylate | 3 | 2009 | 77 | 0.110 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2018 | 293 | 0.110 |
Why?
| | Antipsychotic Agents | 1 | 2017 | 211 | 0.110 |
Why?
| | Aerosols | 1 | 2016 | 146 | 0.110 |
Why?
| | Hepatocytes | 2 | 2006 | 224 | 0.110 |
Why?
| | Gastrectomy | 1 | 2017 | 166 | 0.110 |
Why?
| | Cerebral Cortex | 2 | 2024 | 474 | 0.110 |
Why?
| | Reperfusion Injury | 1 | 2018 | 292 | 0.110 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2015 | 62 | 0.110 |
Why?
| | Sex Characteristics | 3 | 2023 | 789 | 0.110 |
Why?
| | Cholestasis | 3 | 1995 | 214 | 0.110 |
Why?
| | Sulfonamides | 2 | 2025 | 583 | 0.110 |
Why?
| | Larva | 1 | 2016 | 240 | 0.110 |
Why?
| | Blood Chemical Analysis | 1 | 2015 | 109 | 0.110 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 346 | 0.110 |
Why?
| | Piperidines | 1 | 2016 | 222 | 0.100 |
Why?
| | Rabbits | 3 | 2017 | 653 | 0.100 |
Why?
| | Extinction, Psychological | 1 | 2015 | 92 | 0.100 |
Why?
| | Benzamides | 3 | 2009 | 226 | 0.100 |
Why?
| | C-Reactive Protein | 3 | 2022 | 423 | 0.100 |
Why?
| | Pharmacokinetics | 3 | 2020 | 33 | 0.100 |
Why?
| | Rats, Inbred WF | 1 | 2014 | 8 | 0.100 |
Why?
| | HIV Infections | 3 | 2019 | 3195 | 0.100 |
Why?
| | Apoptosis | 4 | 2017 | 2444 | 0.100 |
Why?
| | Linoleic Acids, Conjugated | 1 | 2013 | 7 | 0.100 |
Why?
| | Carbon Isotopes | 2 | 2024 | 143 | 0.100 |
Why?
| | Protein Biosynthesis | 1 | 2017 | 452 | 0.100 |
Why?
| | Specimen Handling | 1 | 2015 | 183 | 0.100 |
Why?
| | DNA Methylation | 1 | 2019 | 690 | 0.100 |
Why?
| | Tidal Volume | 1 | 2014 | 109 | 0.100 |
Why?
| | Diabetes Mellitus, Experimental | 2 | 2006 | 199 | 0.100 |
Why?
| | Least-Squares Analysis | 2 | 2011 | 73 | 0.100 |
Why?
| | Altitude Sickness | 2 | 2006 | 141 | 0.100 |
Why?
| | Prostaglandin D2 | 1 | 2013 | 21 | 0.100 |
Why?
| | Guidelines as Topic | 1 | 2015 | 268 | 0.100 |
Why?
| | United States | 5 | 2020 | 16126 | 0.100 |
Why?
| | Drug Resistance, Multiple | 3 | 2002 | 25 | 0.100 |
Why?
| | Mental Recall | 1 | 2015 | 223 | 0.100 |
Why?
| | 5'-Nucleotidase | 1 | 2013 | 49 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 1969 | 0.100 |
Why?
| | Receptor, Adenosine A2B | 1 | 2013 | 65 | 0.100 |
Why?
| | Fatty Acids | 2 | 2014 | 457 | 0.100 |
Why?
| | Brachial Artery | 3 | 2019 | 208 | 0.100 |
Why?
| | Neutrophil Infiltration | 1 | 2013 | 107 | 0.100 |
Why?
| | S-Adenosylhomocysteine | 1 | 2013 | 24 | 0.100 |
Why?
| | Schizophrenia | 1 | 2017 | 464 | 0.100 |
Why?
| | Adenosine Triphosphate | 4 | 2004 | 500 | 0.100 |
Why?
| | S-Adenosylmethionine | 1 | 2013 | 59 | 0.090 |
Why?
| | MAP Kinase Kinase Kinase 5 | 1 | 2012 | 6 | 0.090 |
Why?
| | Cytoprotection | 1 | 2012 | 56 | 0.090 |
Why?
| | Length of Stay | 1 | 2018 | 1350 | 0.090 |
Why?
| | Ion Transport | 1 | 2012 | 62 | 0.090 |
Why?
| | Polycystic Kidney Diseases | 1 | 2013 | 71 | 0.090 |
Why?
| | Calibration | 4 | 2019 | 152 | 0.090 |
Why?
| | Models, Theoretical | 3 | 2025 | 560 | 0.090 |
Why?
| | Hippocampus | 2 | 2026 | 973 | 0.090 |
Why?
| | Oncogene Proteins | 1 | 2012 | 62 | 0.090 |
Why?
| | Gluconeogenesis | 1 | 2012 | 81 | 0.090 |
Why?
| | Iron | 2 | 2010 | 359 | 0.090 |
Why?
| | Integrins | 1 | 2012 | 90 | 0.090 |
Why?
| | Aging | 2 | 2015 | 1973 | 0.090 |
Why?
| | Equilibrative Nucleoside Transporter 1 | 1 | 2012 | 19 | 0.090 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2012 | 116 | 0.090 |
Why?
| | Fibronectins | 1 | 2012 | 136 | 0.090 |
Why?
| | Graft vs Host Disease | 2 | 2000 | 279 | 0.090 |
Why?
| | Monitoring, Physiologic | 3 | 2012 | 289 | 0.090 |
Why?
| | Follow-Up Studies | 6 | 2025 | 5428 | 0.090 |
Why?
| | Swine, Miniature | 2 | 2010 | 89 | 0.090 |
Why?
| | Cardiac Surgical Procedures | 1 | 2018 | 611 | 0.090 |
Why?
| | Endothelial Cells | 2 | 2018 | 878 | 0.090 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2018 | 668 | 0.090 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 264 | 0.090 |
Why?
| | Scutellaria | 1 | 2011 | 3 | 0.090 |
Why?
| | Scutellaria baicalensis | 1 | 2011 | 4 | 0.090 |
Why?
| | Blood Volume | 1 | 2011 | 65 | 0.080 |
Why?
| | Vagus Nerve | 1 | 2012 | 92 | 0.080 |
Why?
| | Hot Flashes | 1 | 2012 | 92 | 0.080 |
Why?
| | Association Learning | 1 | 2012 | 70 | 0.080 |
Why?
| | Ritonavir | 1 | 2011 | 75 | 0.080 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 165 | 0.080 |
Why?
| | Morphine Derivatives | 1 | 2011 | 19 | 0.080 |
Why?
| | Down Syndrome | 1 | 2018 | 525 | 0.080 |
Why?
| | Mutation, Missense | 1 | 2013 | 335 | 0.080 |
Why?
| | Guideline Adherence | 1 | 2015 | 587 | 0.080 |
Why?
| | Solid Phase Extraction | 1 | 2011 | 25 | 0.080 |
Why?
| | Lung Injury | 1 | 2014 | 249 | 0.080 |
Why?
| | Linear Models | 1 | 2013 | 849 | 0.080 |
Why?
| | Lung | 9 | 2013 | 4116 | 0.080 |
Why?
| | Disease Progression | 4 | 2022 | 2865 | 0.080 |
Why?
| | Cell Cycle | 2 | 2011 | 598 | 0.080 |
Why?
| | Survival Analysis | 2 | 2012 | 1378 | 0.080 |
Why?
| | Internet | 1 | 2015 | 693 | 0.080 |
Why?
| | Methylation | 1 | 2011 | 242 | 0.080 |
Why?
| | Tachyphylaxis | 1 | 2010 | 4 | 0.080 |
Why?
| | Myocardial Ischemia | 1 | 2012 | 285 | 0.080 |
Why?
| | Drug Administration Schedule | 2 | 2006 | 782 | 0.080 |
Why?
| | Cholinergic Agents | 1 | 2010 | 18 | 0.080 |
Why?
| | Structure-Activity Relationship | 5 | 2013 | 563 | 0.080 |
Why?
| | Phenotype | 3 | 2022 | 3170 | 0.080 |
Why?
| | Verapamil | 2 | 2009 | 37 | 0.080 |
Why?
| | Graft Occlusion, Vascular | 2 | 2017 | 40 | 0.080 |
Why?
| | Trigonella | 1 | 2010 | 1 | 0.080 |
Why?
| | Giant Cells | 1 | 2010 | 21 | 0.080 |
Why?
| | Twins, Dizygotic | 1 | 2010 | 108 | 0.080 |
Why?
| | Sensation | 1 | 2010 | 55 | 0.080 |
Why?
| | Peptide Mapping | 1 | 2010 | 62 | 0.080 |
Why?
| | Tablets, Enteric-Coated | 2 | 2007 | 5 | 0.080 |
Why?
| | Twins, Monozygotic | 1 | 2010 | 133 | 0.080 |
Why?
| | Diabetic Nephropathies | 1 | 2013 | 322 | 0.080 |
Why?
| | Needs Assessment | 1 | 2012 | 403 | 0.080 |
Why?
| | Micromonosporaceae | 1 | 2009 | 2 | 0.080 |
Why?
| | Albuminuria | 1 | 2010 | 189 | 0.080 |
Why?
| | Consumer Product Safety | 1 | 2011 | 80 | 0.080 |
Why?
| | Regional Blood Flow | 1 | 2012 | 514 | 0.070 |
Why?
| | Antigens, Plant | 1 | 2010 | 55 | 0.070 |
Why?
| | Proteinuria | 1 | 2010 | 104 | 0.070 |
Why?
| | Diclofenac | 1 | 2009 | 14 | 0.070 |
Why?
| | Conditioning, Classical | 2 | 2024 | 119 | 0.070 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2012 | 457 | 0.070 |
Why?
| | Cell Death | 1 | 2011 | 382 | 0.070 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2012 | 356 | 0.070 |
Why?
| | Respiration, Artificial | 1 | 2014 | 714 | 0.070 |
Why?
| | Infusions, Subcutaneous | 1 | 2009 | 23 | 0.070 |
Why?
| | Risk Factors | 5 | 2025 | 10919 | 0.070 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2012 | 196 | 0.070 |
Why?
| | Administration, Intravenous | 2 | 2021 | 172 | 0.070 |
Why?
| | Cytochrome P-450 Enzyme Inhibitors | 5 | 2000 | 13 | 0.070 |
Why?
| | Surface Properties | 3 | 2019 | 386 | 0.070 |
Why?
| | Neoplasms | 2 | 2016 | 2913 | 0.070 |
Why?
| | Loperamide | 1 | 2009 | 12 | 0.070 |
Why?
| | Radioimmunoassay | 6 | 1996 | 165 | 0.070 |
Why?
| | Cross Reactions | 2 | 2007 | 130 | 0.070 |
Why?
| | Oncogenes | 1 | 2009 | 118 | 0.070 |
Why?
| | Rats, Inbred Strains | 3 | 2015 | 321 | 0.070 |
Why?
| | Creatine | 2 | 2006 | 63 | 0.070 |
Why?
| | Species Specificity | 2 | 2008 | 546 | 0.070 |
Why?
| | Lymphocyte Activation | 6 | 2003 | 1133 | 0.070 |
Why?
| | Aorta | 2 | 2003 | 441 | 0.070 |
Why?
| | Drug Evaluation | 2 | 2000 | 79 | 0.070 |
Why?
| | Kidney Medulla | 1 | 2008 | 31 | 0.070 |
Why?
| | Cytokines | 4 | 2025 | 2069 | 0.070 |
Why?
| | Kidney Tubules, Collecting | 1 | 2008 | 27 | 0.070 |
Why?
| | Automation | 2 | 2016 | 104 | 0.070 |
Why?
| | Guinea Pigs | 1 | 2008 | 159 | 0.070 |
Why?
| | Islets of Langerhans Transplantation | 2 | 2006 | 71 | 0.070 |
Why?
| | Hydroxybutyrates | 2 | 2005 | 15 | 0.070 |
Why?
| | Taste | 2 | 2024 | 238 | 0.070 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2008 | 156 | 0.070 |
Why?
| | Oxidation-Reduction | 2 | 2009 | 1069 | 0.070 |
Why?
| | Rats, Inbred F344 | 1 | 2008 | 268 | 0.070 |
Why?
| | Gulf War | 2 | 2019 | 15 | 0.070 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 271 | 0.070 |
Why?
| | Enzymes | 1 | 2008 | 60 | 0.070 |
Why?
| | Delayed-Action Preparations | 3 | 2017 | 189 | 0.070 |
Why?
| | Allergens | 1 | 2011 | 386 | 0.070 |
Why?
| | Macaca mulatta | 1 | 2008 | 186 | 0.070 |
Why?
| | Feasibility Studies | 3 | 2025 | 1115 | 0.070 |
Why?
| | Receptors, Nicotinic | 1 | 2010 | 327 | 0.070 |
Why?
| | Switzerland | 1 | 2007 | 46 | 0.070 |
Why?
| | Drug Combinations | 3 | 2024 | 396 | 0.060 |
Why?
| | Emulsions | 5 | 2016 | 59 | 0.060 |
Why?
| | Autoanalysis | 1 | 2007 | 8 | 0.060 |
Why?
| | Acute Disease | 6 | 2005 | 1036 | 0.060 |
Why?
| | Antibiotics, Antineoplastic | 3 | 2011 | 140 | 0.060 |
Why?
| | Prosthesis Design | 2 | 2025 | 356 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2019 | 2181 | 0.060 |
Why?
| | NAD | 2 | 2004 | 79 | 0.060 |
Why?
| | ATP-Binding Cassette Transporters | 2 | 2013 | 117 | 0.060 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2007 | 62 | 0.060 |
Why?
| | Serum Albumin | 3 | 2019 | 147 | 0.060 |
Why?
| | Nanoparticles | 1 | 2013 | 517 | 0.060 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 298 | 0.060 |
Why?
| | Cardiotonic Agents | 1 | 2007 | 94 | 0.060 |
Why?
| | Nitric Oxide | 3 | 2017 | 892 | 0.060 |
Why?
| | Caco-2 Cells | 3 | 2003 | 79 | 0.060 |
Why?
| | Fetus | 2 | 2021 | 804 | 0.060 |
Why?
| | Organ Preservation Solutions | 1 | 2006 | 46 | 0.060 |
Why?
| | Lactic Acid | 4 | 2009 | 295 | 0.060 |
Why?
| | Immune Tolerance | 3 | 2017 | 385 | 0.060 |
Why?
| | Epithelial Cells | 1 | 2012 | 1134 | 0.060 |
Why?
| | Narcotic Antagonists | 1 | 2008 | 203 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2009 | 574 | 0.060 |
Why?
| | Body Weight | 5 | 2001 | 972 | 0.060 |
Why?
| | Liver Diseases | 2 | 2024 | 305 | 0.060 |
Why?
| | Glycine Dehydrogenase (Decarboxylating) | 1 | 2026 | 13 | 0.060 |
Why?
| | Macaca | 1 | 2006 | 66 | 0.060 |
Why?
| | Food-Drug Interactions | 1 | 2005 | 11 | 0.060 |
Why?
| | Growth Inhibitors | 1 | 2005 | 39 | 0.060 |
Why?
| | Technology, Pharmaceutical | 1 | 2005 | 30 | 0.060 |
Why?
| | Hematopoietic Stem Cells | 1 | 2009 | 435 | 0.060 |
Why?
| | Triiodothyronine | 1 | 2026 | 55 | 0.060 |
Why?
| | Lactates | 1 | 2005 | 82 | 0.060 |
Why?
| | Methylamines | 1 | 2005 | 39 | 0.060 |
Why?
| | Healthy Volunteers | 1 | 2026 | 219 | 0.060 |
Why?
| | Syndrome | 1 | 2006 | 381 | 0.060 |
Why?
| | Phosphorylation | 5 | 2012 | 1708 | 0.060 |
Why?
| | Thyroid Hormones | 1 | 2026 | 69 | 0.060 |
Why?
| | Ships | 1 | 1985 | 4 | 0.060 |
Why?
| | Exercise | 1 | 2017 | 2205 | 0.060 |
Why?
| | Ultrasonics | 2 | 2002 | 50 | 0.060 |
Why?
| | Organ Preservation | 1 | 2006 | 125 | 0.060 |
Why?
| | Iliac Artery | 2 | 2017 | 55 | 0.060 |
Why?
| | Organ Size | 3 | 2015 | 461 | 0.060 |
Why?
| | Posture | 1 | 2006 | 197 | 0.060 |
Why?
| | Hair | 1 | 2025 | 84 | 0.060 |
Why?
| | Streptozocin | 1 | 2005 | 22 | 0.050 |
Why?
| | Deuterium | 1 | 2005 | 102 | 0.050 |
Why?
| | Triglycerides | 3 | 2011 | 520 | 0.050 |
Why?
| | CD55 Antigens | 1 | 2005 | 29 | 0.050 |
Why?
| | Paraplegia | 1 | 1985 | 60 | 0.050 |
Why?
| | Hot Temperature | 2 | 2012 | 396 | 0.050 |
Why?
| | Complement Inactivator Proteins | 1 | 2005 | 39 | 0.050 |
Why?
| | Echocardiography | 2 | 2024 | 648 | 0.050 |
Why?
| | Colorado | 5 | 2021 | 4556 | 0.050 |
Why?
| | Asthma | 1 | 2016 | 1797 | 0.050 |
Why?
| | Troleandomycin | 3 | 1999 | 3 | 0.050 |
Why?
| | Drug Design | 1 | 2005 | 175 | 0.050 |
Why?
| | Steroids | 2 | 2005 | 160 | 0.050 |
Why?
| | Vasodilation | 2 | 2018 | 521 | 0.050 |
Why?
| | Saccharin | 1 | 2024 | 9 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2005 | 74 | 0.050 |
Why?
| | Warfarin | 1 | 2006 | 179 | 0.050 |
Why?
| | Pulmonary Artery | 2 | 2007 | 1129 | 0.050 |
Why?
| | Calcineurin | 2 | 2004 | 105 | 0.050 |
Why?
| | Propylene Glycols | 1 | 2024 | 28 | 0.050 |
Why?
| | Stress, Psychological | 2 | 2025 | 1151 | 0.050 |
Why?
| | Receptors, Complement | 1 | 2005 | 123 | 0.050 |
Why?
| | Cholesterol, HDL | 2 | 2013 | 201 | 0.050 |
Why?
| | Monoacylglycerol Lipases | 1 | 2024 | 5 | 0.050 |
Why?
| | Trimethylsilyl Compounds | 1 | 2004 | 4 | 0.050 |
Why?
| | Insulin Infusion Systems | 1 | 2009 | 480 | 0.050 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2024 | 11 | 0.050 |
Why?
| | Isotopes | 1 | 2024 | 33 | 0.050 |
Why?
| | Diabetes Mellitus | 1 | 2013 | 1101 | 0.050 |
Why?
| | Neurotoxicity Syndromes | 1 | 2004 | 40 | 0.050 |
Why?
| | DNA | 2 | 2009 | 1437 | 0.050 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2009 | 883 | 0.050 |
Why?
| | Analysis of Variance | 2 | 1997 | 1300 | 0.050 |
Why?
| | Saliva | 1 | 2025 | 249 | 0.050 |
Why?
| | Glycerol | 1 | 2024 | 90 | 0.050 |
Why?
| | Antitubercular Agents | 1 | 2005 | 208 | 0.050 |
Why?
| | Plant Leaves | 1 | 2024 | 131 | 0.050 |
Why?
| | Coronary Angiography | 1 | 2025 | 328 | 0.050 |
Why?
| | Protein Binding | 3 | 2018 | 2240 | 0.050 |
Why?
| | Tumor Cells, Cultured | 3 | 2001 | 887 | 0.050 |
Why?
| | Obesity | 1 | 2017 | 3118 | 0.050 |
Why?
| | Midazolam | 1 | 2003 | 73 | 0.050 |
Why?
| | Immunocompromised Host | 1 | 2005 | 202 | 0.050 |
Why?
| | Oxidative Phosphorylation | 1 | 2004 | 209 | 0.050 |
Why?
| | Tomography, Optical Coherence | 1 | 2025 | 270 | 0.050 |
Why?
| | Memory, Short-Term | 1 | 2026 | 269 | 0.050 |
Why?
| | Altitude | 3 | 2017 | 463 | 0.050 |
Why?
| | Complement Membrane Attack Complex | 2 | 2018 | 38 | 0.050 |
Why?
| | NADP | 2 | 1994 | 52 | 0.050 |
Why?
| | Pancreas Transplantation | 1 | 2003 | 71 | 0.050 |
Why?
| | Insulin | 3 | 2009 | 2516 | 0.050 |
Why?
| | Renal Insufficiency | 1 | 2005 | 172 | 0.050 |
Why?
| | Surveys and Questionnaires | 1 | 2015 | 6085 | 0.050 |
Why?
| | Bacterial Proteins | 1 | 2009 | 968 | 0.050 |
Why?
| | Leukocytes | 1 | 2024 | 296 | 0.050 |
Why?
| | Ketoconazole | 2 | 1999 | 3 | 0.050 |
Why?
| | Chemistry, Pharmaceutical | 2 | 2000 | 112 | 0.050 |
Why?
| | Sports | 1 | 1985 | 212 | 0.050 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 3 | 2010 | 347 | 0.050 |
Why?
| | Trauma Centers | 1 | 2025 | 466 | 0.050 |
Why?
| | Myelin Sheath | 1 | 2024 | 166 | 0.050 |
Why?
| | Isoflurane | 1 | 2002 | 41 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2005 | 552 | 0.040 |
Why?
| | Oral Mucosal Absorption | 1 | 2021 | 1 | 0.040 |
Why?
| | Hepatobiliary Elimination | 1 | 2021 | 1 | 0.040 |
Why?
| | Administration, Sublingual | 1 | 2021 | 12 | 0.040 |
Why?
| | Oligodendroglia | 1 | 2024 | 190 | 0.040 |
Why?
| | Reperfusion | 1 | 2002 | 54 | 0.040 |
Why?
| | Wine | 1 | 2001 | 13 | 0.040 |
Why?
| | Cognition | 2 | 2023 | 1271 | 0.040 |
Why?
| | Drug Dosage Calculations | 1 | 2021 | 27 | 0.040 |
Why?
| | Plant Preparations | 1 | 2002 | 37 | 0.040 |
Why?
| | Oxaloacetic Acid | 1 | 2001 | 4 | 0.040 |
Why?
| | B7-1 Antigen | 1 | 2001 | 55 | 0.040 |
Why?
| | Cross-Sectional Studies | 3 | 2021 | 5925 | 0.040 |
Why?
| | Mice, Mutant Strains | 1 | 2022 | 302 | 0.040 |
Why?
| | Biological Transport | 2 | 2003 | 424 | 0.040 |
Why?
| | Drug Overdose | 1 | 2006 | 375 | 0.040 |
Why?
| | Cell Survival | 3 | 2012 | 1104 | 0.040 |
Why?
| | Hyperthermia, Induced | 1 | 2002 | 120 | 0.040 |
Why?
| | Psychotropic Drugs | 1 | 2002 | 78 | 0.040 |
Why?
| | Pregnancy Trimester, Third | 1 | 2021 | 119 | 0.040 |
Why?
| | Behavior, Animal | 1 | 2024 | 520 | 0.040 |
Why?
| | Aspartic Acid | 1 | 2001 | 88 | 0.040 |
Why?
| | Motivation | 1 | 2026 | 602 | 0.040 |
Why?
| | Glomerular Mesangium | 2 | 1991 | 21 | 0.040 |
Why?
| | Microchemistry | 3 | 2000 | 19 | 0.040 |
Why?
| | Tryptophan | 1 | 2022 | 182 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2021 | 89 | 0.040 |
Why?
| | Self Report | 1 | 2025 | 876 | 0.040 |
Why?
| | Gene Silencing | 2 | 2012 | 202 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2020 | 1723 | 0.040 |
Why?
| | Haplotypes | 2 | 2013 | 500 | 0.040 |
Why?
| | Breast Feeding | 1 | 2024 | 447 | 0.040 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2000 | 49 | 0.040 |
Why?
| | Sequence Alignment | 2 | 2013 | 362 | 0.040 |
Why?
| | Membrane Glycoproteins | 2 | 2001 | 499 | 0.040 |
Why?
| | Databases, Genetic | 1 | 2022 | 238 | 0.040 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 2123 | 0.040 |
Why?
| | Aorta, Abdominal | 1 | 2000 | 52 | 0.040 |
Why?
| | 2,4-Dinitrophenol | 1 | 2000 | 9 | 0.040 |
Why?
| | LLC-PK1 Cells | 1 | 2000 | 18 | 0.040 |
Why?
| | DNA, Complementary | 1 | 2000 | 273 | 0.040 |
Why?
| | Antimetabolites | 1 | 2000 | 21 | 0.040 |
Why?
| | Reward | 1 | 2022 | 248 | 0.040 |
Why?
| | Monte Carlo Method | 1 | 2020 | 148 | 0.040 |
Why?
| | Logistic Models | 2 | 2022 | 2139 | 0.040 |
Why?
| | 2-Propanol | 1 | 2019 | 20 | 0.040 |
Why?
| | Pyrazoles | 1 | 2004 | 517 | 0.040 |
Why?
| | Pulmonary Alveoli | 1 | 2002 | 387 | 0.040 |
Why?
| | Child Development | 1 | 2024 | 483 | 0.040 |
Why?
| | Heart | 1 | 2003 | 626 | 0.040 |
Why?
| | Transplantation, Heterotopic | 1 | 1999 | 16 | 0.040 |
Why?
| | Risk Assessment | 3 | 2018 | 3752 | 0.040 |
Why?
| | Rats, Inbred BN | 4 | 2000 | 56 | 0.040 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 82 | 0.040 |
Why?
| | Eicosanoids | 1 | 2019 | 58 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2020 | 196 | 0.040 |
Why?
| | Blood Glucose | 2 | 2009 | 2344 | 0.040 |
Why?
| | K562 Cells | 2 | 2009 | 92 | 0.040 |
Why?
| | Pituitary-Adrenal System | 1 | 2020 | 164 | 0.040 |
Why?
| | Citrus | 1 | 1999 | 12 | 0.040 |
Why?
| | Diet | 2 | 2019 | 1278 | 0.040 |
Why?
| | Epithelium | 1 | 2000 | 311 | 0.040 |
Why?
| | Individuality | 1 | 2000 | 149 | 0.040 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2020 | 199 | 0.040 |
Why?
| | Maternal Age | 1 | 2019 | 128 | 0.040 |
Why?
| | Antibodies, Monoclonal | 3 | 2001 | 1505 | 0.040 |
Why?
| | Beverages | 1 | 1999 | 68 | 0.040 |
Why?
| | Complement C4a | 1 | 2018 | 9 | 0.040 |
Why?
| | Hypertension | 1 | 2007 | 1276 | 0.030 |
Why?
| | Complement C5a | 1 | 2018 | 54 | 0.030 |
Why?
| | Amides | 1 | 1999 | 101 | 0.030 |
Why?
| | Antigens, CD | 1 | 2001 | 558 | 0.030 |
Why?
| | Analgesics | 1 | 2020 | 231 | 0.030 |
Why?
| | Ultrafiltration | 1 | 2018 | 28 | 0.030 |
Why?
| | Food Hypersensitivity | 2 | 2011 | 164 | 0.030 |
Why?
| | Drug Liberation | 1 | 2018 | 36 | 0.030 |
Why?
| | Europe | 1 | 1999 | 421 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2014 | 1165 | 0.030 |
Why?
| | F2-Isoprostanes | 2 | 2009 | 21 | 0.030 |
Why?
| | Sus scrofa | 1 | 2018 | 65 | 0.030 |
Why?
| | Glomerulonephritis, Membranoproliferative | 1 | 2018 | 25 | 0.030 |
Why?
| | Solutions | 2 | 2016 | 159 | 0.030 |
Why?
| | Ions | 1 | 2018 | 66 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 195 | 0.030 |
Why?
| | Serum Albumin, Bovine | 1 | 2018 | 62 | 0.030 |
Why?
| | Tissue Culture Techniques | 1 | 2018 | 82 | 0.030 |
Why?
| | Nifedipine | 1 | 1997 | 27 | 0.030 |
Why?
| | Hyperlipidemias | 1 | 1998 | 120 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2020 | 421 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 1998 | 95 | 0.030 |
Why?
| | Nitriles | 1 | 1999 | 211 | 0.030 |
Why?
| | Bioreactors | 1 | 2018 | 50 | 0.030 |
Why?
| | Urea | 1 | 2018 | 85 | 0.030 |
Why?
| | Neoplasm Proteins | 2 | 2013 | 442 | 0.030 |
Why?
| | Bronchi | 1 | 1999 | 263 | 0.030 |
Why?
| | Injections, Intravenous | 2 | 2011 | 197 | 0.030 |
Why?
| | Intestines | 1 | 2000 | 354 | 0.030 |
Why?
| | Veterans Health | 1 | 2019 | 190 | 0.030 |
Why?
| | Weight Gain | 1 | 2001 | 561 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 2013 | 2131 | 0.030 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2017 | 68 | 0.030 |
Why?
| | Archaeal Proteins | 1 | 2017 | 50 | 0.030 |
Why?
| | Environmental Monitoring | 1 | 2019 | 347 | 0.030 |
Why?
| | Cholesterol, VLDL | 1 | 1996 | 5 | 0.030 |
Why?
| | Schizophrenic Psychology | 1 | 2017 | 99 | 0.030 |
Why?
| | Anxiety | 1 | 2024 | 1122 | 0.030 |
Why?
| | Postoperative Care | 1 | 1999 | 286 | 0.030 |
Why?
| | Microscopy, Electron, Transmission | 2 | 2008 | 156 | 0.030 |
Why?
| | Temperature | 1 | 2000 | 633 | 0.030 |
Why?
| | Malates | 1 | 2016 | 8 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2013 | 2883 | 0.030 |
Why?
| | Postmenopause | 1 | 2019 | 394 | 0.030 |
Why?
| | Pharmacogenomic Testing | 1 | 2017 | 63 | 0.030 |
Why?
| | Hydrolysis | 2 | 2013 | 197 | 0.030 |
Why?
| | Women's Health | 1 | 2019 | 316 | 0.030 |
Why?
| | Catheterization | 1 | 2017 | 184 | 0.030 |
Why?
| | Cytochrome P-450 CYP2E1 | 1 | 1996 | 30 | 0.030 |
Why?
| | Stroke | 1 | 2006 | 1271 | 0.030 |
Why?
| | Cell Count | 2 | 2013 | 319 | 0.030 |
Why?
| | Urinary Tract Infections | 1 | 2019 | 210 | 0.030 |
Why?
| | Betaine | 1 | 2016 | 67 | 0.030 |
Why?
| | Anterior Chamber | 1 | 1996 | 26 | 0.030 |
Why?
| | Materials Testing | 1 | 2018 | 345 | 0.030 |
Why?
| | Anesthesia, Intravenous | 1 | 2016 | 24 | 0.030 |
Why?
| | Nutritional Status | 1 | 2019 | 353 | 0.030 |
Why?
| | Leukotriene B4 | 1 | 2016 | 36 | 0.030 |
Why?
| | Bromocriptine | 1 | 1996 | 31 | 0.030 |
Why?
| | Nonlinear Dynamics | 1 | 2016 | 93 | 0.030 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2010 | 2602 | 0.030 |
Why?
| | Nicotinic Agonists | 1 | 2017 | 135 | 0.030 |
Why?
| | Gastric Mucosa | 1 | 1996 | 54 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 735 | 0.030 |
Why?
| | Duodenum | 1 | 1996 | 77 | 0.030 |
Why?
| | Body Mass Index | 1 | 2024 | 2447 | 0.030 |
Why?
| | Artificial Organs | 1 | 1995 | 2 | 0.030 |
Why?
| | Syringes | 1 | 2016 | 49 | 0.030 |
Why?
| | Epitopes | 1 | 2018 | 473 | 0.030 |
Why?
| | Infant, Premature | 1 | 2020 | 620 | 0.030 |
Why?
| | 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2015 | 5 | 0.030 |
Why?
| | Linoleic Acids | 1 | 2015 | 6 | 0.030 |
Why?
| | Health Policy | 1 | 1999 | 400 | 0.030 |
Why?
| | Hypertension, Pulmonary | 1 | 2007 | 1957 | 0.030 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2015 | 35 | 0.030 |
Why?
| | Incidence | 2 | 2018 | 2934 | 0.030 |
Why?
| | Neuroglia | 1 | 1996 | 174 | 0.030 |
Why?
| | RNA, Viral | 1 | 2019 | 693 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2016 | 396 | 0.030 |
Why?
| | Estradiol | 1 | 2019 | 515 | 0.030 |
Why?
| | Citric Acid Cycle | 2 | 2010 | 58 | 0.030 |
Why?
| | Asialoglycoproteins | 1 | 1995 | 2 | 0.030 |
Why?
| | Lipids | 1 | 2020 | 707 | 0.030 |
Why?
| | Complement System Proteins | 1 | 2018 | 314 | 0.030 |
Why?
| | Rhodamines | 1 | 1995 | 19 | 0.030 |
Why?
| | Safety | 1 | 2017 | 358 | 0.030 |
Why?
| | Heat-Shock Proteins | 2 | 2007 | 139 | 0.030 |
Why?
| | alpha-Fetoproteins | 1 | 1995 | 42 | 0.030 |
Why?
| | Physical Conditioning, Animal | 1 | 2017 | 242 | 0.030 |
Why?
| | Precision Medicine | 1 | 2019 | 461 | 0.030 |
Why?
| | Cholesterol, LDL | 1 | 1996 | 360 | 0.030 |
Why?
| | Oxides | 1 | 1995 | 47 | 0.030 |
Why?
| | Lipoproteins, VLDL | 1 | 2014 | 21 | 0.030 |
Why?
| | Uteroglobin | 1 | 2014 | 31 | 0.030 |
Why?
| | Extracellular Matrix | 2 | 1996 | 563 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 441 | 0.030 |
Why?
| | Particle Size | 1 | 2016 | 381 | 0.030 |
Why?
| | Respiratory Tract Infections | 1 | 2019 | 396 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2016 | 571 | 0.030 |
Why?
| | Pain Measurement | 2 | 2010 | 562 | 0.030 |
Why?
| | Ferric Compounds | 1 | 1995 | 54 | 0.030 |
Why?
| | Nitrites | 1 | 2014 | 88 | 0.030 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2014 | 66 | 0.030 |
Why?
| | Kidney Function Tests | 3 | 2006 | 156 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2015 | 440 | 0.030 |
Why?
| | Dasatinib | 1 | 2014 | 58 | 0.030 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2013 | 17 | 0.030 |
Why?
| | Mesangial Cells | 1 | 2013 | 4 | 0.030 |
Why?
| | Nitrates | 1 | 2014 | 96 | 0.030 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2013 | 20 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2018 | 1038 | 0.030 |
Why?
| | Insufflation | 1 | 2013 | 14 | 0.030 |
Why?
| | Nevirapine | 1 | 2013 | 18 | 0.020 |
Why?
| | Benzoxazines | 1 | 2013 | 31 | 0.020 |
Why?
| | Thiazoles | 1 | 2014 | 142 | 0.020 |
Why?
| | Spectrophotometry, Ultraviolet | 2 | 1999 | 81 | 0.020 |
Why?
| | Cyclopropanes | 1 | 2013 | 84 | 0.020 |
Why?
| | Phospholipases | 1 | 2013 | 14 | 0.020 |
Why?
| | Alkynes | 1 | 2013 | 67 | 0.020 |
Why?
| | Mannitol | 2 | 2006 | 40 | 0.020 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2013 | 23 | 0.020 |
Why?
| | Peripheral Arterial Disease | 1 | 2020 | 509 | 0.020 |
Why?
| | Models, Molecular | 2 | 2013 | 1599 | 0.020 |
Why?
| | Cognition Disorders | 1 | 2017 | 544 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2399 | 0.020 |
Why?
| | bcl-2-Associated X Protein | 1 | 2012 | 53 | 0.020 |
Why?
| | Protein Deglycase DJ-1 | 1 | 2012 | 15 | 0.020 |
Why?
| | Mothers | 1 | 2019 | 766 | 0.020 |
Why?
| | Organoplatinum Compounds | 1 | 2012 | 65 | 0.020 |
Why?
| | Smoking | 1 | 2020 | 1477 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 1995 | 372 | 0.020 |
Why?
| | Body Composition | 1 | 2016 | 693 | 0.020 |
Why?
| | Complement C3 | 1 | 2013 | 187 | 0.020 |
Why?
| | Leucovorin | 1 | 2012 | 98 | 0.020 |
Why?
| | Heart Rate | 2 | 2009 | 856 | 0.020 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2012 | 75 | 0.020 |
Why?
| | Laparoscopy | 1 | 2017 | 481 | 0.020 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2012 | 88 | 0.020 |
Why?
| | Vascular System Injuries | 1 | 2013 | 81 | 0.020 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2013 | 145 | 0.020 |
Why?
| | Nucleoside Transport Proteins | 1 | 2012 | 8 | 0.020 |
Why?
| | No-Reflow Phenomenon | 1 | 2012 | 7 | 0.020 |
Why?
| | Asialoglycoprotein Receptor | 2 | 2006 | 6 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2012 | 211 | 0.020 |
Why?
| | Dipyridamole | 1 | 2012 | 28 | 0.020 |
Why?
| | Receptors, Purinergic P1 | 1 | 2012 | 30 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2012 | 194 | 0.020 |
Why?
| | Heart Ventricles | 2 | 2007 | 756 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2015 | 784 | 0.020 |
Why?
| | Methylcholanthrene | 1 | 1991 | 21 | 0.020 |
Why?
| | Phenobarbital | 1 | 1991 | 21 | 0.020 |
Why?
| | Proteolysis | 1 | 2012 | 172 | 0.020 |
Why?
| | Fear | 1 | 2015 | 368 | 0.020 |
Why?
| | Chimerism | 1 | 2012 | 35 | 0.020 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 174 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2009 | 3937 | 0.020 |
Why?
| | Darunavir | 1 | 2011 | 20 | 0.020 |
Why?
| | Dealkylation | 1 | 1991 | 3 | 0.020 |
Why?
| | Actins | 2 | 2007 | 426 | 0.020 |
Why?
| | Hemodynamics | 1 | 2017 | 1118 | 0.020 |
Why?
| | Femoral Artery | 1 | 2013 | 190 | 0.020 |
Why?
| | Protein Multimerization | 1 | 2013 | 205 | 0.020 |
Why?
| | Glucuronates | 1 | 1991 | 5 | 0.020 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2012 | 73 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2013 | 279 | 0.020 |
Why?
| | Spectrophotometry, Infrared | 1 | 1991 | 54 | 0.020 |
Why?
| | Spectrometry, Mass, Fast Atom Bombardment | 1 | 1991 | 7 | 0.020 |
Why?
| | Contrast Media | 1 | 1995 | 497 | 0.020 |
Why?
| | Fluorouracil | 1 | 2012 | 231 | 0.020 |
Why?
| | Overweight | 1 | 2016 | 614 | 0.020 |
Why?
| | Chemical Fractionation | 1 | 1991 | 29 | 0.020 |
Why?
| | Centrifugation | 1 | 1991 | 28 | 0.020 |
Why?
| | Immunoenzyme Techniques | 3 | 1996 | 200 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2016 | 578 | 0.020 |
Why?
| | Cytoskeleton | 1 | 2012 | 192 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2013 | 371 | 0.020 |
Why?
| | Food Analysis | 1 | 2011 | 22 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 2012 | 2601 | 0.020 |
Why?
| | Alfentanil | 1 | 2010 | 7 | 0.020 |
Why?
| | Aldehydes | 1 | 1991 | 140 | 0.020 |
Why?
| | Ki-67 Antigen | 1 | 2011 | 118 | 0.020 |
Why?
| | Pain Perception | 1 | 2010 | 24 | 0.020 |
Why?
| | Cell Division | 3 | 2001 | 757 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 638 | 0.020 |
Why?
| | Mice, Inbred DBA | 1 | 2010 | 182 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2933 | 0.020 |
Why?
| | Serologic Tests | 1 | 2010 | 54 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2013 | 858 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2016 | 1150 | 0.020 |
Why?
| | Protein Conformation | 1 | 2013 | 938 | 0.020 |
Why?
| | Blood | 2 | 2000 | 107 | 0.020 |
Why?
| | Alleles | 1 | 2013 | 896 | 0.020 |
Why?
| | Spinacia oleracea | 1 | 2009 | 10 | 0.020 |
Why?
| | Granuloma | 1 | 2010 | 97 | 0.020 |
Why?
| | Proteins | 1 | 1995 | 1023 | 0.020 |
Why?
| | Fibrin | 1 | 2010 | 84 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2011 | 177 | 0.020 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2014 | 376 | 0.020 |
Why?
| | Blood-Brain Barrier | 1 | 2010 | 160 | 0.020 |
Why?
| | Elective Surgical Procedures | 1 | 2011 | 203 | 0.020 |
Why?
| | Prostaglandins A | 1 | 2009 | 9 | 0.020 |
Why?
| | Spectrum Analysis | 1 | 2009 | 85 | 0.020 |
Why?
| | Serbia | 1 | 2008 | 7 | 0.020 |
Why?
| | Insulin Lispro | 1 | 2009 | 42 | 0.020 |
Why?
| | Succinic Acid | 1 | 2009 | 46 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 615 | 0.020 |
Why?
| | Deoxyglucose | 1 | 2009 | 51 | 0.020 |
Why?
| | Free Radicals | 1 | 2009 | 105 | 0.020 |
Why?
| | Binding, Competitive | 1 | 2009 | 185 | 0.020 |
Why?
| | Bronchoscopy | 2 | 2000 | 227 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2011 | 383 | 0.020 |
Why?
| | Urinalysis | 1 | 2009 | 83 | 0.020 |
Why?
| | Cohort Studies | 1 | 2019 | 6033 | 0.020 |
Why?
| | Osmotic Pressure | 1 | 2008 | 41 | 0.020 |
Why?
| | Saline Solution, Hypertonic | 1 | 2008 | 43 | 0.020 |
Why?
| | Molecular Weight | 1 | 1988 | 312 | 0.020 |
Why?
| | Monocrotaline | 1 | 2007 | 31 | 0.020 |
Why?
| | HSP27 Heat-Shock Proteins | 1 | 2007 | 13 | 0.020 |
Why?
| | Naloxone | 1 | 2009 | 132 | 0.020 |
Why?
| | T-Lymphocytes | 2 | 2004 | 1998 | 0.020 |
Why?
| | Fasting | 1 | 2009 | 279 | 0.020 |
Why?
| | Up-Regulation | 1 | 2010 | 848 | 0.020 |
Why?
| | Wound Healing | 1 | 2010 | 355 | 0.020 |
Why?
| | HIV-1 | 1 | 2013 | 908 | 0.020 |
Why?
| | Ventricular Pressure | 1 | 2007 | 52 | 0.020 |
Why?
| | Technetium | 1 | 2006 | 10 | 0.020 |
Why?
| | Animals, Outbred Strains | 1 | 2006 | 6 | 0.020 |
Why?
| | Antibodies, Heterophile | 1 | 2006 | 12 | 0.020 |
Why?
| | Systole | 1 | 2007 | 181 | 0.020 |
Why?
| | Statistics as Topic | 1 | 1988 | 283 | 0.020 |
Why?
| | Radiography | 2 | 2000 | 853 | 0.020 |
Why?
| | Cell Size | 2 | 1997 | 93 | 0.020 |
Why?
| | Dosage Forms | 2 | 1996 | 11 | 0.020 |
Why?
| | Cell Transplantation | 1 | 2006 | 39 | 0.020 |
Why?
| | Serum Albumin, Human | 1 | 2006 | 7 | 0.020 |
Why?
| | Raffinose | 1 | 2006 | 29 | 0.020 |
Why?
| | Lysine | 1 | 2009 | 305 | 0.020 |
Why?
| | Procaine | 1 | 2006 | 10 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1261 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 2006 | 116 | 0.020 |
Why?
| | Potassium Chloride | 1 | 2006 | 40 | 0.020 |
Why?
| | Muscle, Smooth | 1 | 2007 | 153 | 0.020 |
Why?
| | Insulin, Regular, Human | 1 | 2006 | 47 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2006 | 120 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2009 | 778 | 0.020 |
Why?
| | Allopurinol | 1 | 2006 | 70 | 0.010 |
Why?
| | Portal System | 1 | 2006 | 12 | 0.010 |
Why?
| | Insulin, Long-Acting | 1 | 2006 | 65 | 0.010 |
Why?
| | Random Allocation | 1 | 2007 | 365 | 0.010 |
Why?
| | Biopsy | 2 | 2000 | 1082 | 0.010 |
Why?
| | Cold Ischemia | 1 | 2006 | 40 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 979 | 0.010 |
Why?
| | Contraindications | 1 | 2006 | 90 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2006 | 247 | 0.010 |
Why?
| | Myocardial Contraction | 1 | 2007 | 293 | 0.010 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2006 | 78 | 0.010 |
Why?
| | Electroencephalography | 1 | 2009 | 563 | 0.010 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2005 | 196 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2013 | 2968 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2009 | 380 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2006 | 330 | 0.010 |
Why?
| | Escherichia coli | 1 | 2009 | 835 | 0.010 |
Why?
| | Drug Compounding | 1 | 2005 | 107 | 0.010 |
Why?
| | Microscopy, Electron | 2 | 1996 | 414 | 0.010 |
Why?
| | Travel | 1 | 2006 | 136 | 0.010 |
Why?
| | Nanostructures | 1 | 2005 | 105 | 0.010 |
Why?
| | Spleen | 1 | 2006 | 508 | 0.010 |
Why?
| | Gene Expression | 1 | 2009 | 1478 | 0.010 |
Why?
| | Mitochondrial Encephalomyopathies | 1 | 2004 | 9 | 0.010 |
Why?
| | Treatment Failure | 1 | 2005 | 360 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2007 | 1043 | 0.010 |
Why?
| | Motor Skills | 1 | 1985 | 104 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2009 | 2191 | 0.010 |
Why?
| | Polymers | 1 | 2008 | 485 | 0.010 |
Why?
| | Animals, Genetically Modified | 1 | 2005 | 247 | 0.010 |
Why?
| | Blood Coagulation | 1 | 2006 | 274 | 0.010 |
Why?
| | Absorption | 1 | 2003 | 60 | 0.010 |
Why?
| | HSP72 Heat-Shock Proteins | 1 | 2003 | 31 | 0.010 |
Why?
| | Stroke Volume | 1 | 2007 | 655 | 0.010 |
Why?
| | Adenosine Diphosphate | 1 | 2003 | 83 | 0.010 |
Why?
| | NFATC Transcription Factors | 1 | 2004 | 94 | 0.010 |
Why?
| | Prevalence | 1 | 2010 | 2875 | 0.010 |
Why?
| | Ventricular Function, Left | 1 | 2007 | 544 | 0.010 |
Why?
| | Cardiac Output | 1 | 2003 | 179 | 0.010 |
Why?
| | Coronary Circulation | 1 | 2003 | 134 | 0.010 |
Why?
| | Odds Ratio | 1 | 2006 | 1083 | 0.010 |
Why?
| | gamma-Glutamyltransferase | 2 | 1994 | 42 | 0.010 |
Why?
| | Chromatography, Gas | 1 | 2002 | 30 | 0.010 |
Why?
| | Hospitals, University | 1 | 2003 | 176 | 0.010 |
Why?
| | Alanine | 1 | 2003 | 169 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2003 | 196 | 0.010 |
Why?
| | Alkaline Phosphatase | 2 | 1994 | 144 | 0.010 |
Why?
| | Rhodamine 123 | 1 | 2001 | 8 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 1995 | 3916 | 0.010 |
Why?
| | B7-2 Antigen | 1 | 2001 | 27 | 0.010 |
Why?
| | Microcirculation | 1 | 2002 | 142 | 0.010 |
Why?
| | Transplantation Immunology | 1 | 2001 | 29 | 0.010 |
Why?
| | Transfection | 1 | 2003 | 927 | 0.010 |
Why?
| | Calorimetry | 1 | 2001 | 69 | 0.010 |
Why?
| | Chronic Disease | 1 | 2007 | 1812 | 0.010 |
Why?
| | Molecular Conformation | 1 | 2001 | 141 | 0.010 |
Why?
| | Quantum Theory | 1 | 2001 | 86 | 0.010 |
Why?
| | Cell Membrane | 2 | 1995 | 709 | 0.010 |
Why?
| | Coronary Vessels | 1 | 2002 | 246 | 0.010 |
Why?
| | Coloring Agents | 1 | 2000 | 89 | 0.010 |
Why?
| | Blood Pressure | 1 | 2007 | 1782 | 0.010 |
Why?
| | Receptors, Interleukin-2 | 1 | 2000 | 64 | 0.010 |
Why?
| | Cattle | 1 | 2002 | 946 | 0.010 |
Why?
| | Autopsy | 1 | 2000 | 94 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 2 | 1991 | 49 | 0.010 |
Why?
| | Atrial Fibrillation | 1 | 2006 | 558 | 0.010 |
Why?
| | Diuretics, Osmotic | 1 | 1999 | 2 | 0.010 |
Why?
| | Islets of Langerhans | 1 | 2006 | 847 | 0.010 |
Why?
| | Doxorubicin | 1 | 2001 | 403 | 0.010 |
Why?
| | Crotonates | 1 | 1999 | 7 | 0.010 |
Why?
| | Toluidines | 1 | 1999 | 10 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2007 | 2805 | 0.010 |
Why?
| | Remission Induction | 1 | 2000 | 306 | 0.010 |
Why?
| | Thermodynamics | 1 | 2001 | 419 | 0.010 |
Why?
| | Capsules | 2 | 1990 | 42 | 0.010 |
Why?
| | Vinblastine | 1 | 1999 | 75 | 0.010 |
Why?
| | Ultrasonography | 1 | 2003 | 788 | 0.010 |
Why?
| | Postoperative Period | 1 | 2000 | 351 | 0.010 |
Why?
| | Indicators and Reagents | 1 | 1999 | 106 | 0.010 |
Why?
| | Isoxazoles | 1 | 1999 | 56 | 0.010 |
Why?
| | Nuclear Proteins | 1 | 2004 | 740 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 1999 | 428 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 1999 | 528 | 0.010 |
Why?
| | Aniline Compounds | 1 | 1999 | 120 | 0.010 |
Why?
| | Radiography, Thoracic | 1 | 1999 | 172 | 0.010 |
Why?
| | Binding Sites | 1 | 2001 | 1311 | 0.010 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2000 | 450 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 666 | 0.010 |
Why?
| | Cytosol | 1 | 1997 | 213 | 0.010 |
Why?
| | Spectrometry, Mass, Secondary Ion | 1 | 1996 | 2 | 0.010 |
Why?
| | Acetic Anhydrides | 1 | 1996 | 3 | 0.010 |
Why?
| | Azathioprine | 1 | 1996 | 44 | 0.010 |
Why?
| | Computer Simulation | 1 | 2001 | 1003 | 0.010 |
Why?
| | Tissue Donors | 1 | 2000 | 420 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2004 | 1482 | 0.010 |
Why?
| | Membrane Lipids | 1 | 1996 | 82 | 0.010 |
Why?
| | Administration, Topical | 1 | 1996 | 155 | 0.010 |
Why?
| | Ophthalmic Solutions | 1 | 1996 | 82 | 0.010 |
Why?
| | Acetonitriles | 1 | 1995 | 12 | 0.010 |
Why?
| | Bile Canaliculi | 1 | 1995 | 4 | 0.010 |
Why?
| | Transcription Factors | 1 | 2004 | 1736 | 0.010 |
Why?
| | Albumins | 1 | 1996 | 119 | 0.010 |
Why?
| | Immunoblotting | 1 | 1995 | 295 | 0.010 |
Why?
| | Fetuins | 1 | 1995 | 3 | 0.010 |
Why?
| | Antifungal Agents | 1 | 1996 | 152 | 0.010 |
Why?
| | Cornea | 1 | 1996 | 154 | 0.010 |
Why?
| | Blood Specimen Collection | 1 | 1995 | 37 | 0.010 |
Why?
| | Ferrosoferric Oxide | 1 | 1995 | 25 | 0.010 |
Why?
| | Cataract Extraction | 1 | 1996 | 120 | 0.010 |
Why?
| | Cytomegalovirus Infections | 1 | 1996 | 206 | 0.010 |
Why?
| | Skin | 1 | 1999 | 754 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1994 | 164 | 0.010 |
Why?
| | Vasodilator Agents | 1 | 1996 | 330 | 0.010 |
Why?
| | Antibody Specificity | 1 | 1994 | 179 | 0.010 |
Why?
| | Cell Adhesion | 1 | 1995 | 451 | 0.010 |
Why?
| | Vinca Alkaloids | 1 | 1993 | 6 | 0.010 |
Why?
| | Affinity Labels | 1 | 1993 | 16 | 0.010 |
Why?
| | Daunorubicin | 1 | 1993 | 25 | 0.010 |
Why?
| | Succinimides | 1 | 1993 | 21 | 0.010 |
Why?
| | Collagen | 1 | 1996 | 457 | 0.010 |
Why?
| | Bile Acids and Salts | 1 | 1994 | 163 | 0.010 |
Why?
| | Cricetulus | 1 | 1993 | 118 | 0.010 |
Why?
| | CHO Cells | 1 | 1993 | 169 | 0.010 |
Why?
| | Algorithms | 1 | 2001 | 1851 | 0.010 |
Why?
| | Cricetinae | 1 | 1993 | 305 | 0.010 |
Why?
| | Norpregnenes | 1 | 1992 | 4 | 0.010 |
Why?
| | Drug Resistance | 1 | 1993 | 145 | 0.010 |
Why?
| | Tritium | 1 | 1992 | 67 | 0.010 |
Why?
| | Water | 1 | 1995 | 448 | 0.010 |
Why?
| | Glutamate Dehydrogenase | 1 | 1991 | 4 | 0.010 |
Why?
| | Cholinesterases | 1 | 1991 | 9 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1991 | 168 | 0.010 |
Why?
| | Aspartate Aminotransferases | 1 | 1991 | 85 | 0.010 |
Why?
| | Alanine Transaminase | 1 | 1991 | 151 | 0.000 |
Why?
| | Oils | 1 | 1990 | 22 | 0.000 |
Why?
| | Carrier Proteins | 1 | 1993 | 729 | 0.000 |
Why?
| | Antigen-Antibody Reactions | 1 | 1987 | 49 | 0.000 |
Why?
| | Gelatin | 1 | 1988 | 56 | 0.000 |
Why?
| | Liver Neoplasms | 1 | 1994 | 777 | 0.000 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 1987 | 104 | 0.000 |
Why?
| | CD3 Complex | 1 | 1987 | 112 | 0.000 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1987 | 673 | 0.000 |
Why?
|
|
Christians's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|